CrystalGenomics Completes Phase 1 Clinical Trial of Fibrosis Treatment ‘CG-750’

[Asia Economy Reporter Hyunseok Yoo] CrystalGenomics announced on the 22nd that it has completed the Phase 1 clinical trial of the fibrosis treatment drug ‘CG-750’.

This clinical trial was conducted at Seoul National University Hospital with 25 healthy adult males to compare and evaluate the safety and pharmacokinetics of the capsule formulation ‘CG-750’ and the intravenous injection formulation ‘CG-745’.

The purpose of the trial was to compare and evaluate the bioavailability and safety of the oral formulation ‘CG-750’ against the intravenous injection formulation ‘CG-745’, thereby securing safety and pharmacokinetic evaluation data for the fibrosis treatment drug ‘CG-750’.

Through this, CrystalGenomics plans to officially begin developing ‘CG-750’ as a treatment for various fibrosis indications, including IPF (Idiopathic Pulmonary Fibrosis, 특발성 폐섬유증).

Additionally, the possibility of developing an oral formulation to improve medication convenience for the ‘CG-745’ intravenous injection formulation was also confirmed. The development of an oral formulation is expected to enhance patient convenience and reduce economic burden. Patients can continue treatment through medication in daily life without having to visit the hospital each time. In the case of the existing injection, patients must visit the hospital to receive intravenous administration, which is inconvenient.

Fibrosis refers to the process of damaged tissue becoming fibrotic, with pulmonary and renal fibrosis being representative diseases. Recently, patients who have recovered from COVID-19 are receiving treatment in Korea for pulmonary fibrosis as a sequela, where the lungs harden, making it a disease of growing attention.

Going forward, the final clinical study report (CSR) of the single ascending dose (SAD) Phase 1 trial will be prepared and used as a basis for entering subsequent clinical trials. A CrystalGenomics official stated, “As fibrosis occurrence has been reported as a sequela of COVID-19 recently, expectations for the development of treatments are higher than ever.”